topotecan has been researched along with Kidney Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beijnen, JH; Herben, VM; ten Bokkel Huinink, WW | 1 |
| Chen, TL; Donehower, RC; Ettinger, DS; Forastiere, AA; Grochow, LB; O'Reilly, S; Rowinsky, EK; Sartorius, S; Slichenmyer, W | 1 |
| Armstrong, DK; Grochow, LB; O'Reilly, S | 1 |
1 review(s) available for topotecan and Kidney Diseases
| Article | Year |
|---|---|
Clinical pharmacokinetics of topotecan.
Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Half-Life; Humans; Kidney Diseases; Liver Diseases; Metabolic Clearance Rate; Topoisomerase I Inhibitors; Topotecan | 1996 |
1 trial(s) available for topotecan and Kidney Diseases
| Article | Year |
|---|---|
Phase I and pharmacologic study of topotecan in patients with impaired renal function.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Neoplasms; Reference Values; Topotecan | 1996 |
1 other study(ies) available for topotecan and Kidney Diseases
| Article | Year |
|---|---|
Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan.
Topics: Bone Marrow; Female; Humans; Kidney Diseases; Ovarian Neoplasms; Topotecan | 1997 |